In a recent Xconomy article on cancer DNA testing, Cancer Commons medical director Kevin Knopf shares his perspective:
“To help all patients we think an open-source database has the most utility,” says Knopf. Instead of current tests that list a patient’s mutations and potential drugs to use, a report should rank therapies the way online travel sites rank best options.
Oncologist and Cancer Commons Medical Director Kevin Knopf, MD, will speak next month at TiEcon 2017, a technology conference in Santa Clara, CA. He’ll join three other experts to discuss the future of personalized medicine. From the program:
A new era of personalized medicine has made its way into the world of healthcare. We will discuss novel approaches for designing disease treatment and prevention that integrates with an individual’s genetic profile, environment and lifestyle.The future is here — let’s hear from industry luminaries on how digital health entrepreneurs and the healthcare industry as a whole are preparing for massive disruption.
Kevin’s presentation will take place on May 5 at 3:00 pm. For more information, visit the TiEcon website.
In a new interview, oncologist and Cancer Commons Medical Director Dr. Kevin Knopf gives his perspective on the future of cancer research and treatment, including the role of Cancer Commons. He also discusses the potential benefits of value frameworks, which are tools that take a variety of factors into account in order to aid treatment decisions.